The Improvement of Cardiac Performance by Amrinone, a New Cardiotonic Drug, in an Experimental Failing Heart Preparation of the Dog

Keisuke SATOH, M.D., Masahiko MARUYAMA, B.S., and Norio Taira, M.D.

SUMMARY

The cardiac effects of amrinone were studied in 5 heart-lung preparations of the dog. Amrinone improved the cardiac performance during pentobarbital-induced heart failure.

Additional Indexing Words:
Amrinone  Heart-lung preparation  Heart failure  Positive inotropic action

Amrinone is a new orally effective cardiotonic drug developed for the treatment of the congestive heart failure.1,2 The drug has a definite positive inotropic action in normal in situ hearts of the dog,1,2 isolated Langendorff preparations of the guinea pig,3 isolated papillary muscles or atria of the cat1,3 and rabbit,3 and isolated blood-perfused papillary muscles of the dog.4 However, the extent to which amrinone improves cardiac performance during experimentally-induced heart failure is equivocal. Farah and Alousi1 reported that amrinone completely restored the cardiac function curve of dog heart-lung preparations after induction of heart failure by pentobarbital administration, whereas Onuaguluchi and Tanz3 reported that the force of contraction of the guinea-pig Langendorff preparation depressed by verapamil failed to attain control values after amrinone administration.3 Furthermore, Farah and Alousi1 did not discuss how amrinone affected the heart rate and force of contraction of the dog heart-lung preparations. The present experiments were designed to obtain detailed information about the effects of amrinone on the failing heart. We used the dog heart-lung preparation in which cardiac failure was produced by pentobarbital.

From the Department of Pharmacology, Tohoku University School of Medicine, Sendai 980, Japan.

Received for publication February 15, 1982.

975
MATERIALS AND METHODS

The heart-lung preparation of the dog was used. The method used was essentially the same as described elsewhere in detail, except that electronic measuring devices were used. Five mongrel dogs, weighing 7–10 Kg, were anesthetized with sodium pentobarbital (30 mg/Kg, i.v.). Blood coagulation was prevented with sodium heparin (500 units/Kg, i.v.). The volume of blood primed in the venous reservoir was 300–750 ml. The cardiac output was measured with an electromagnetic flow meter (Nihon Kohden, MF-46). The right atrial pressure was measured with a pressure transducer (Nihon Kohden, LPU-0.1). The force of contraction was measured with a Walton-Brodie strain-gauge arch, stitched to the surface of the left ventricle. The heart rate was measured with a heart rate meter (San-ei Instrument, 2040) triggered by R waves of lead II of ECG. All recordings were made on a rectilinear recorder (San-ei Instrument, 8S). To determine the ability of the heart to respond to an increased venous supply, the inflow level (height of the venous reservoir) was raised stepwise to 5 cm and 10 cm above the basal level (competence test). At each inflow level a competence index was obtained by dividing the increase in right atrial pressure (cm H₂O) by 5 cm or 10 cm (elevated height of the venous reservoir), and the cardiac function curves were constructed. Amrinone (Sterling-Winthrop) was dissolved in 0.1 N lactic acid in a concentration of 10 mg/ml. The amrinone solution was administered into the venous reservoir in a cumulative way. The results are expressed as mean values±SEM, unless otherwise stated. Student’s t-test was used and a p value less than 0.05 was considered significant.

RESULTS

When basal cardiac variables were stable, sodium pentobarbital was administered into the reservoir in 50 mg steps up to a total of 90±22 (S.D.) mg (n=5). With these doses of sodium pentobarbital, the cardiac output, heart rate, and force of contraction decreased and the right atrial pressure

| Table I. The Values of Cardiac Variables before and after Pentobarbital Administration |
|-------------------------------------|-----------------|-----------------|-----------------|-----------------|
|                                    | Cardiac output (ml/min) | Right atrial pressure (cm H₂O) | Heart rate (beats/min) | Contractility (%) |
| Control                            | 740±81           | 2.5±0.6         | 145±10          | 100             |
| Pentobarbital treatment            |                  |                 |                 |                 |
| 90±22 (S.D.) mg                    | 538±58*          | 4.0±0.6*        | 132±11*         | 58.5±9*         |

* Significantly different from control values.
Amrinone and dog heart lung-preparation

Fig. 1. Effects of amrinone on the cardiac output, right atrial pressure, heart rate, and force of contraction in a heart-lung preparation of the dog. CT = competence test.

Fig. 2. Cardiac function curves obtained by elevating the height of the venous reservoir. Control (□), failure (●). Amrinone in cumulative doses: 1 mg (△), 3 mg (▲), 10 mg (□), 30 mg (■).

increased gradually (Figs. 1, 2). The mean decreases in cardiac output and force of contraction, attained after the final dose of pentobarbital, were about 30% and 40% of respective controls. The values of cardiac variables before and after the final pentobarbital dose are shown in Table I. Under these conditions, amrinone was administered cumulatively into the reservoir in doses ranging from 1 mg to a total of 30 mg. One of experiments is illustrated in Fig. 1 and the summarized results from 5 preparations are shown in Figs. 2, 3, and 4. Amrinone administration gradually increased the cardiac output (Figs. 1, 2), force of contraction and heart rate (Figs. 1, 3), and decreased the right atrial pressure (Figs. 1, 2) in a dose-dependent manner. These actions of amrinone were slow in onset and long-lasting. The force of contraction recovered completely with 10 mg of amrinone and increased further beyond the
control value (the value before pentobarbital) with a 30 mg dose (Fig. 3). The heart rate was restored to the control value with 30 mg of amrinone (Fig. 3). The cardiac function curve, depressed by pentobarbital, was re-
stored by 10 and 30 mg of amrinone to the values which were not significantly different from the controls. Nevertheless, the restored cardiac function curves were located to the right of the control curves (Fig. 2). The competence index also recovered to values not significantly different from the control with 10 and 30 mg of amrinone (Fig. 4). Amrinone caused no arrhythmias at all dose levels tested.

**Discussion**

During experimental heart failure induced by pentobarbital in the dog heart-lung preparation, amrinone produced increases in cardiac output, force of contraction, and heart rate, and a decrease in right atrial pressure. The values of these cardiac variables after amrinone administration were not significantly different from the control values (the values before pentobarbital). The competence index also recovered to the control value. Thus, the present results are consistent with those obtained by Farah and Alousi\(^1\) from the same sort of preparation\(^1\) but are at variance with those obtained from the guinea-pig Langendorff preparation, where heart failure was induced by verapamil.\(^3\) At present, it is not clear whether the discrepancy is due to differences in species, preparations or cardiodepressant drugs. Although the results are roughly consistent with those obtained by Farah and Alousi,\(^1\) the restoration of the cardiac function curves after amrinone administration was different. In their experiments, the cardiac function curves depressed by pentobarbital were shifted to left of the control curve after administration of 10 mg of amrinone. On the other hand, in the present experiments, the cardiac function curve, depressed in a similar way, was located to the right of the control curve even with 30 mg of amrinone.

It is clear that amrinone is a rather weak cardiotonic drug, as assessed in the present experimental heart failure model. Nevertheless, amrinone is still a potential drug for heart failure.\(^7,8\) Amrinone, unlike catecholamines, has been reported to increase the heart rate only slightly in doses which produce a sizable increase in force of contraction.\(^1^1 - 3^\) In the present experiments, doses of amrinone which restored the cardiac function curve virtually to the control did not increase the heart rate beyond the control value. Furthermore, amrinone, unlike digitalis, produced no arrhythmias. Digitalis is also known to be a vasoconstrictor. As opposed to digitalis, amrinone has a coronary vasodilator action that increases the supply of oxygen to the myocardium,\(^4,8\) and a peripheral vasodilator action which reduces the load on the failing heart.\(^10\) In addition to these actions, amrinone has a tracheodilator action in the dog.\(^1^1\)
ACKNOWLEDGMENT

We are grateful to Sterling-Winthrop Research Institute, New York, USA for a generous supply of amrinone.

REFERENCES